Share Price and Basic Stock Data
Last Updated: December 10, 2025, 11:23 pm
| PEG Ratio | 2.51 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Denis Chem Lab Ltd operates in the chemical manufacturing sector, where it has carved out a niche over the years. The company reported a sales figure of ₹161 Cr for the fiscal year ending March 2023, showcasing a steady growth trajectory from ₹136 Cr in the previous year. This upward momentum has continued into FY 2024, with sales projected at ₹167 Cr. Notably, quarterly sales have shown resilience, with the most recent quarter (September 2023) recording ₹45.43 Cr, a testament to its ability to navigate market fluctuations. The trend indicates a robust demand environment, particularly as the company has consistently improved its quarterly figures despite minor dips, such as the ₹37.33 Cr reported in December 2022. Investors may find comfort in this trend, as it underscores a capacity for adaptation and growth in a competitive landscape.
Profitability and Efficiency Metrics
Profitability metrics for Denis Chem Lab present a mixed yet promising picture. The operating profit margin (OPM) for the most recent fiscal year stood at 9%, reflecting a decline from 13% in FY 2024. However, the company has managed to maintain a healthy return on equity (ROE) of 9.77% and return on capital employed (ROCE) at 13.9%. These figures highlight the firm’s ability to generate returns for its shareholders, albeit with some efficiency challenges. The interest coverage ratio (ICR) is notably strong at 36.21x, indicating that the company’s earnings are more than sufficient to cover its interest obligations. This suggests a sound operational structure, although the decline in OPM could be a point of concern for investors keen on sustained profitability. Overall, while profitability metrics show some strain, the underlying efficiency ratios appear robust.
Balance Sheet Strength and Financial Ratios
Denis Chem Lab’s balance sheet reflects a strong financial position, with total borrowings reported at a mere ₹8 Cr, which is significantly low compared to its reserves of ₹74 Cr. This results in a low debt-to-equity ratio, indicating a conservative approach towards leveraging, which is generally favorable in terms of financial stability. The current ratio is strong at 2.70, suggesting that the company has ample short-term assets to cover its liabilities, further enhancing its liquidity position. However, the price-to-book value ratio of 1.51x indicates that the stock is trading at a slight premium to its book value, which may raise questions about valuation among certain investors. Nevertheless, the combination of low debt and sufficient reserves paints a picture of a company well-equipped to handle unforeseen challenges.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Denis Chem Lab Ltd reveals a predominantly public ownership structure, with 61% of shares held by the public and only 38.98% by promoters. This distribution could suggest a level of confidence among retail investors, especially given the stable performance metrics over recent years. Interestingly, Foreign Institutional Investors (FIIs) have minimal exposure, holding just 0.01% of shares, which might imply a lack of international interest or awareness in the stock. The number of shareholders has been on the rise, growing from 3,432 in December 2022 to 7,304 by September 2025, indicating increasing retail interest. This trend can be seen as a positive sign, reflecting growing confidence in the company’s potential and operational sustainability.
Outlook, Risks, and Final Insight
Looking ahead, Denis Chem Lab faces a mix of opportunities and challenges. On the one hand, the steady revenue growth and strong balance sheet position suggest that the company is well-placed to capitalize on market demands. However, investors should remain cautious about the declining profitability margins, particularly the recent dip in OPM, which could signal rising costs or pricing pressures. Additionally, the lack of institutional backing could be a double-edged sword; while it may suggest a more grassroots investor base, it also raises concerns about the company’s visibility and perceived attractiveness to larger investors. For retail investors, the key will be to monitor the company’s ability to sustain its growth trajectory while managing costs effectively. The overall sentiment appears cautiously optimistic, but vigilance regarding operational efficiency and market dynamics will be essential for making informed investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Denis Chem Lab Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 106 Cr. | 27.6 | 796/25.8 | 1.03 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 1,595 Cr. | 158 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 46.8 Cr. | 3.67 | 8.65/3.55 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,573.17 Cr | 221.47 | 428.03 | 219.27 | 0.25% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39.29 | 44.51 | 37.33 | 39.73 | 42.48 | 45.43 | 40.06 | 39.85 | 41.26 | 47.82 | 42.84 | 41.38 | 43.28 |
| Expenses | 34.99 | 38.74 | 33.38 | 34.99 | 37.45 | 40.29 | 34.07 | 34.77 | 36.91 | 41.94 | 39.01 | 39.32 | 38.46 |
| Operating Profit | 4.30 | 5.77 | 3.95 | 4.74 | 5.03 | 5.14 | 5.99 | 5.08 | 4.35 | 5.88 | 3.83 | 2.06 | 4.82 |
| OPM % | 10.94% | 12.96% | 10.58% | 11.93% | 11.84% | 11.31% | 14.95% | 12.75% | 10.54% | 12.30% | 8.94% | 4.98% | 11.14% |
| Other Income | 0.08 | 0.11 | 0.07 | 0.34 | 0.01 | 0.52 | 0.26 | 0.59 | 0.32 | 0.58 | 0.30 | 1.17 | 0.30 |
| Interest | 0.17 | 0.08 | 0.12 | 0.26 | 0.09 | 0.09 | 0.13 | 0.23 | 0.12 | 0.09 | 0.07 | 0.23 | 0.19 |
| Depreciation | 1.36 | 1.37 | 1.37 | 3.72 | 1.59 | 1.76 | 1.84 | 1.75 | 1.63 | 1.66 | 1.84 | 1.73 | 1.61 |
| Profit before tax | 2.85 | 4.43 | 2.53 | 1.10 | 3.36 | 3.81 | 4.28 | 3.69 | 2.92 | 4.71 | 2.22 | 1.27 | 3.32 |
| Tax % | 24.91% | 29.80% | 28.06% | 29.09% | 20.24% | 33.07% | 25.23% | 26.02% | 28.77% | 25.05% | 20.72% | 44.09% | 25.30% |
| Net Profit | 2.15 | 3.11 | 1.83 | 0.78 | 2.68 | 2.54 | 3.20 | 2.73 | 2.08 | 3.53 | 1.76 | 0.71 | 2.48 |
| EPS in Rs | 1.55 | 2.24 | 1.32 | 0.56 | 1.93 | 1.83 | 2.31 | 1.97 | 1.50 | 2.54 | 1.27 | 0.51 | 1.79 |
Last Updated: August 19, 2025, 8:15 pm
Below is a detailed analysis of the quarterly data for Denis Chem Lab Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 43.28 Cr.. The value appears strong and on an upward trend. It has increased from 41.38 Cr. (Mar 2025) to 43.28 Cr., marking an increase of 1.90 Cr..
- For Expenses, as of Jun 2025, the value is 38.46 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 39.32 Cr. (Mar 2025) to 38.46 Cr., marking a decrease of 0.86 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.82 Cr.. The value appears strong and on an upward trend. It has increased from 2.06 Cr. (Mar 2025) to 4.82 Cr., marking an increase of 2.76 Cr..
- For OPM %, as of Jun 2025, the value is 11.14%. The value appears strong and on an upward trend. It has increased from 4.98% (Mar 2025) to 11.14%, marking an increase of 6.16%.
- For Other Income, as of Jun 2025, the value is 0.30 Cr.. The value appears to be declining and may need further review. It has decreased from 1.17 Cr. (Mar 2025) to 0.30 Cr., marking a decrease of 0.87 Cr..
- For Interest, as of Jun 2025, the value is 0.19 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.23 Cr. (Mar 2025) to 0.19 Cr., marking a decrease of 0.04 Cr..
- For Depreciation, as of Jun 2025, the value is 1.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.73 Cr. (Mar 2025) to 1.61 Cr., marking a decrease of 0.12 Cr..
- For Profit before tax, as of Jun 2025, the value is 3.32 Cr.. The value appears strong and on an upward trend. It has increased from 1.27 Cr. (Mar 2025) to 3.32 Cr., marking an increase of 2.05 Cr..
- For Tax %, as of Jun 2025, the value is 25.30%. The value appears to be improving (decreasing) as expected. It has decreased from 44.09% (Mar 2025) to 25.30%, marking a decrease of 18.79%.
- For Net Profit, as of Jun 2025, the value is 2.48 Cr.. The value appears strong and on an upward trend. It has increased from 0.71 Cr. (Mar 2025) to 2.48 Cr., marking an increase of 1.77 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.79. The value appears strong and on an upward trend. It has increased from 0.51 (Mar 2025) to 1.79, marking an increase of 1.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:32 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67 | 75 | 98 | 112 | 107 | 123 | 135 | 109 | 136 | 161 | 167 | 173 | 175 |
| Expenses | 60 | 66 | 89 | 98 | 95 | 110 | 120 | 99 | 122 | 142 | 146 | 157 | 159 |
| Operating Profit | 6 | 9 | 8 | 14 | 12 | 14 | 15 | 10 | 14 | 19 | 21 | 16 | 17 |
| OPM % | 9% | 12% | 9% | 12% | 11% | 11% | 11% | 9% | 11% | 12% | 13% | 9% | 9% |
| Other Income | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 2 | 2 |
| Interest | 3 | 5 | 7 | 6 | 5 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 4 | 6 | 7 | 6 | 6 | 7 | 6 | 6 | 8 | 7 | 7 | 7 |
| Profit before tax | 2 | 0 | -3 | 2 | 2 | 6 | 6 | 3 | 9 | 11 | 15 | 11 | 12 |
| Tax % | 41% | 78% | 30% | 37% | -5% | -7% | 26% | 27% | 30% | 28% | 26% | 27% | |
| Net Profit | 1 | 0 | -4 | 1 | 2 | 6 | 4 | 2 | 6 | 8 | 11 | 8 | 8 |
| EPS in Rs | 1.17 | 0.07 | -4.16 | 0.89 | 1.54 | 4.58 | 3.03 | 1.63 | 4.51 | 5.66 | 8.04 | 5.82 | 6.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 22% | 0% | 46% | 33% | 35% | 31% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | 125.00% | 100.00% | 200.00% | -33.33% | -50.00% | 200.00% | 33.33% | 37.50% | -27.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | 225.00% | -25.00% | 100.00% | -233.33% | -16.67% | 250.00% | -166.67% | 4.17% | -64.77% |
Denis Chem Lab Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 5% |
| 3 Years: | 8% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 14% |
| 3 Years: | 9% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 10% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 10% |
| 3 Years: | 12% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:44 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 9 | 9 | 12 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 6 | 8 | 7 | 18 | 36 | 43 | 45 | 48 | 53 | 58 | 66 | 71 | 74 |
| Borrowings | 31 | 48 | 44 | 37 | 25 | 23 | 14 | 9 | 3 | 2 | 1 | 1 | 8 |
| Other Liabilities | 12 | 17 | 24 | 27 | 26 | 26 | 25 | 22 | 27 | 25 | 28 | 26 | 28 |
| Total Liabilities | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 112 | 124 |
| Fixed Assets | 9 | 42 | 40 | 44 | 40 | 50 | 46 | 41 | 42 | 35 | 38 | 39 | 36 |
| CWIP | 9 | 0 | 10 | 1 | 5 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 34 | 39 | 35 | 49 | 56 | 55 | 52 | 51 | 55 | 62 | 72 | 73 | 85 |
| Total Assets | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 99 | 109 | 112 | 124 |
Below is a detailed analysis of the balance sheet data for Denis Chem Lab Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 74.00 Cr.. The value appears strong and on an upward trend. It has increased from 71.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 28.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.00 Cr. (Mar 2025) to 28.00 Cr., marking an increase of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 124.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 112.00 Cr. (Mar 2025) to 124.00 Cr., marking an increase of 12.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 36.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 3.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 85.00 Cr.. The value appears strong and on an upward trend. It has increased from 73.00 Cr. (Mar 2025) to 85.00 Cr., marking an increase of 12.00 Cr..
- For Total Assets, as of Sep 2025, the value is 124.00 Cr.. The value appears strong and on an upward trend. It has increased from 112.00 Cr. (Mar 2025) to 124.00 Cr., marking an increase of 12.00 Cr..
Notably, the Reserves (74.00 Cr.) exceed the Borrowings (8.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -39.00 | -36.00 | -23.00 | -13.00 | -9.00 | 1.00 | 1.00 | 11.00 | 17.00 | 20.00 | 15.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 123 | 85 | 104 | 105 | 106 | 94 | 110 | 85 | 71 | 69 | 65 |
| Inventory Days | 37 | 40 | 39 | 35 | 52 | 50 | 51 | 60 | 50 | 39 | 43 | 37 |
| Days Payable | 53 | 81 | 119 | 136 | 150 | 102 | 108 | 103 | 99 | 79 | 90 | 81 |
| Cash Conversion Cycle | 75 | 81 | 4 | 3 | 8 | 55 | 37 | 67 | 36 | 31 | 22 | 21 |
| Working Capital Days | 32 | -19 | -57 | -13 | 4 | 17 | 32 | 63 | 51 | 41 | 37 | 38 |
| ROCE % | 16% | 11% | 5% | 12% | 9% | 11% | 11% | 6% | 14% | 16% | 20% | 14% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 5.82 | 8.04 | 5.66 | 4.51 | 1.63 |
| Diluted EPS (Rs.) | 5.82 | 8.04 | 5.66 | 4.51 | 1.63 |
| Cash EPS (Rs.) | 10.76 | 13.04 | 11.30 | 8.66 | 5.92 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 61.33 | 57.91 | 52.08 | 47.89 | 44.32 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 61.33 | 57.91 | 52.08 | 47.89 | 44.32 |
| Dividend / Share (Rs.) | 1.50 | 2.50 | 2.00 | 1.50 | 0.75 |
| Revenue From Operations / Share (Rs.) | 124.89 | 120.94 | 115.91 | 98.41 | 78.78 |
| PBDIT / Share (Rs.) | 13.32 | 16.30 | 13.96 | 11.10 | 7.64 |
| PBIT / Share (Rs.) | 8.38 | 11.30 | 8.33 | 6.95 | 3.34 |
| PBT / Share (Rs.) | 8.01 | 10.90 | 7.87 | 6.40 | 2.22 |
| Net Profit / Share (Rs.) | 5.82 | 8.04 | 5.66 | 4.51 | 1.63 |
| PBDIT Margin (%) | 10.66 | 13.47 | 12.04 | 11.27 | 9.69 |
| PBIT Margin (%) | 6.70 | 9.34 | 7.18 | 7.05 | 4.24 |
| PBT Margin (%) | 6.41 | 9.01 | 6.78 | 6.50 | 2.82 |
| Net Profit Margin (%) | 4.66 | 6.64 | 4.88 | 4.58 | 2.07 |
| Return on Networth / Equity (%) | 9.48 | 13.88 | 10.87 | 9.42 | 3.68 |
| Return on Capital Employeed (%) | 13.49 | 19.08 | 15.33 | 13.56 | 6.81 |
| Return On Assets (%) | 7.19 | 10.20 | 7.90 | 6.49 | 2.45 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.03 | 0.07 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.02 | 0.04 | 0.14 |
| Asset Turnover Ratio (%) | 1.56 | 1.61 | 1.64 | 1.45 | 1.15 |
| Current Ratio (X) | 2.70 | 2.55 | 2.46 | 2.11 | 2.01 |
| Quick Ratio (X) | 2.32 | 2.18 | 2.08 | 1.72 | 1.63 |
| Inventory Turnover Ratio (X) | 17.33 | 8.28 | 7.87 | 7.19 | 6.33 |
| Dividend Payout Ratio (NP) (%) | 42.95 | 24.87 | 26.48 | 16.61 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 23.22 | 15.33 | 13.27 | 8.65 | 0.00 |
| Earning Retention Ratio (%) | 57.05 | 75.13 | 73.52 | 83.39 | 0.00 |
| Cash Earning Retention Ratio (%) | 76.78 | 84.67 | 86.73 | 91.35 | 0.00 |
| Interest Coverage Ratio (X) | 36.21 | 41.64 | 30.21 | 20.36 | 6.82 |
| Interest Coverage Ratio (Post Tax) (X) | 16.82 | 21.54 | 13.26 | 9.28 | 2.46 |
| Enterprise Value (Cr.) | 103.15 | 185.70 | 73.51 | 88.57 | 56.43 |
| EV / Net Operating Revenue (X) | 0.59 | 1.11 | 0.45 | 0.64 | 0.51 |
| EV / EBITDA (X) | 5.58 | 8.21 | 3.79 | 5.75 | 5.32 |
| MarketCap / Net Operating Revenue (X) | 0.74 | 1.25 | 0.55 | 0.69 | 0.47 |
| Retention Ratios (%) | 57.04 | 75.12 | 73.51 | 83.38 | 0.00 |
| Price / BV (X) | 1.51 | 2.60 | 1.22 | 1.42 | 0.84 |
| Price / Net Operating Revenue (X) | 0.74 | 1.25 | 0.55 | 0.69 | 0.47 |
| EarningsYield | 0.06 | 0.05 | 0.08 | 0.06 | 0.04 |
After reviewing the key financial ratios for Denis Chem Lab Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 8.04 (Mar 24) to 5.82, marking a decrease of 2.22.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 8.04 (Mar 24) to 5.82, marking a decrease of 2.22.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.76. This value is within the healthy range. It has decreased from 13.04 (Mar 24) to 10.76, marking a decrease of 2.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 61.33. It has increased from 57.91 (Mar 24) to 61.33, marking an increase of 3.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 61.33. It has increased from 57.91 (Mar 24) to 61.33, marking an increase of 3.42.
- For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.50 (Mar 24) to 1.50, marking a decrease of 1.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 124.89. It has increased from 120.94 (Mar 24) to 124.89, marking an increase of 3.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.32. This value is within the healthy range. It has decreased from 16.30 (Mar 24) to 13.32, marking a decrease of 2.98.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.38. This value is within the healthy range. It has decreased from 11.30 (Mar 24) to 8.38, marking a decrease of 2.92.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.01. This value is within the healthy range. It has decreased from 10.90 (Mar 24) to 8.01, marking a decrease of 2.89.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 8.04 (Mar 24) to 5.82, marking a decrease of 2.22.
- For PBDIT Margin (%), as of Mar 25, the value is 10.66. This value is within the healthy range. It has decreased from 13.47 (Mar 24) to 10.66, marking a decrease of 2.81.
- For PBIT Margin (%), as of Mar 25, the value is 6.70. This value is below the healthy minimum of 10. It has decreased from 9.34 (Mar 24) to 6.70, marking a decrease of 2.64.
- For PBT Margin (%), as of Mar 25, the value is 6.41. This value is below the healthy minimum of 10. It has decreased from 9.01 (Mar 24) to 6.41, marking a decrease of 2.60.
- For Net Profit Margin (%), as of Mar 25, the value is 4.66. This value is below the healthy minimum of 5. It has decreased from 6.64 (Mar 24) to 4.66, marking a decrease of 1.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 15. It has decreased from 13.88 (Mar 24) to 9.48, marking a decrease of 4.40.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.49. This value is within the healthy range. It has decreased from 19.08 (Mar 24) to 13.49, marking a decrease of 5.59.
- For Return On Assets (%), as of Mar 25, the value is 7.19. This value is within the healthy range. It has decreased from 10.20 (Mar 24) to 7.19, marking a decrease of 3.01.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.56. It has decreased from 1.61 (Mar 24) to 1.56, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has increased from 2.55 (Mar 24) to 2.70, marking an increase of 0.15.
- For Quick Ratio (X), as of Mar 25, the value is 2.32. This value exceeds the healthy maximum of 2. It has increased from 2.18 (Mar 24) to 2.32, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 17.33. This value exceeds the healthy maximum of 8. It has increased from 8.28 (Mar 24) to 17.33, marking an increase of 9.05.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 42.95. This value is within the healthy range. It has increased from 24.87 (Mar 24) to 42.95, marking an increase of 18.08.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 23.22. This value is within the healthy range. It has increased from 15.33 (Mar 24) to 23.22, marking an increase of 7.89.
- For Earning Retention Ratio (%), as of Mar 25, the value is 57.05. This value is within the healthy range. It has decreased from 75.13 (Mar 24) to 57.05, marking a decrease of 18.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 76.78. This value exceeds the healthy maximum of 70. It has decreased from 84.67 (Mar 24) to 76.78, marking a decrease of 7.89.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 36.21. This value is within the healthy range. It has decreased from 41.64 (Mar 24) to 36.21, marking a decrease of 5.43.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 16.82. This value is within the healthy range. It has decreased from 21.54 (Mar 24) to 16.82, marking a decrease of 4.72.
- For Enterprise Value (Cr.), as of Mar 25, the value is 103.15. It has decreased from 185.70 (Mar 24) to 103.15, marking a decrease of 82.55.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.11 (Mar 24) to 0.59, marking a decrease of 0.52.
- For EV / EBITDA (X), as of Mar 25, the value is 5.58. This value is within the healthy range. It has decreased from 8.21 (Mar 24) to 5.58, marking a decrease of 2.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 1.25 (Mar 24) to 0.74, marking a decrease of 0.51.
- For Retention Ratios (%), as of Mar 25, the value is 57.04. This value is within the healthy range. It has decreased from 75.12 (Mar 24) to 57.04, marking a decrease of 18.08.
- For Price / BV (X), as of Mar 25, the value is 1.51. This value is within the healthy range. It has decreased from 2.60 (Mar 24) to 1.51, marking a decrease of 1.09.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 1.25 (Mar 24) to 0.74, marking a decrease of 0.51.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 0.06, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Denis Chem Lab Ltd:
- Net Profit Margin: 4.66%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.49% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.48% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 16.82
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.32
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 15.7 (Industry average Stock P/E: 428.03)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.66%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | Block No. 457, Village : Chhatral, Gandhi Nagar Dist. Gujarat 382729 | denischem401@gmail.com http://www.denischemlab.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dinesh B Patel | Chairman |
| Dr. Himanshu C Patel | Managing Director |
| Mr. Dipak Patel | Independent Director |
| Mr. Hemang Patel | Independent Director |
| Mr. Hemendrakumar C Shah | Independent Director |
| Ms. Anar H Patel | Director |
FAQ
What is the intrinsic value of Denis Chem Lab Ltd?
Denis Chem Lab Ltd's intrinsic value (as of 11 December 2025) is 78.99 which is 2.72% lower the current market price of 81.20, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 113 Cr. market cap, FY2025-2026 high/low of 193/78.0, reserves of ₹74 Cr, and liabilities of 124 Cr.
What is the Market Cap of Denis Chem Lab Ltd?
The Market Cap of Denis Chem Lab Ltd is 113 Cr..
What is the current Stock Price of Denis Chem Lab Ltd as on 11 December 2025?
The current stock price of Denis Chem Lab Ltd as on 11 December 2025 is 81.2.
What is the High / Low of Denis Chem Lab Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Denis Chem Lab Ltd stocks is 193/78.0.
What is the Stock P/E of Denis Chem Lab Ltd?
The Stock P/E of Denis Chem Lab Ltd is 15.7.
What is the Book Value of Denis Chem Lab Ltd?
The Book Value of Denis Chem Lab Ltd is 63.2.
What is the Dividend Yield of Denis Chem Lab Ltd?
The Dividend Yield of Denis Chem Lab Ltd is 1.85 %.
What is the ROCE of Denis Chem Lab Ltd?
The ROCE of Denis Chem Lab Ltd is 13.9 %.
What is the ROE of Denis Chem Lab Ltd?
The ROE of Denis Chem Lab Ltd is 9.77 %.
What is the Face Value of Denis Chem Lab Ltd?
The Face Value of Denis Chem Lab Ltd is 10.0.